INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Key facts

Sponsor

Inovio Pharmaceuticals

Principal Investigator

Jeffrey Skolnik, MD

Inovio Pharmaceuticals

Intervention

INO-5401(biological)

Enrollment

52 target

Eligibility

18 years · All sexes

Timeline

2018 – 2026

Study locations (21)

• City of Hope, Duarte, California, United States
• Stanford University, School of Medicine, Palo Alto, California, United States
• University of California, San Francisco, San Francisco, California, United States
• University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Henry Ford Health System, Detroit, Michigan, United States
• Rutgers University - Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
• New York University Langone Medical Center; Perlmutter Cancer Center, New York, New York, United States
• Icahn School of Medicine at Mount Sinai, New York, New York, United States
• Columbia University Medical Center The Neurological Institute of New York, New York, New York, United States
• New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
• University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States
• Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
• +6 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Embryonal tumor of neuroepithelial tissue

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07488754
  Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
  Medical University of Warsaw
• RECRUITINGPHASE1NCT07025018
  Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
  Hutchmed
• RECRUITINGNANCT06719440
  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
  Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• RECRUITINGPHASE2NCT06558214
  OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
  University of Florida
• RECRUITINGPHASE3NCT06496971
  A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
  NaviFUS Corporation
• RECRUITINGPHASE2NCT07364786
  Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
  Peter Siesjö
• RECRUITINGEARLY PHASE1NCT06828341
  A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
  JIANG LONGWEI
• RECRUITINGPHASE2NCT05708352
  A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
  Cedars-Sinai Medical Center

See all trials for Embryonal tumor of neuroepithelial tissue →